The combination of a group of anti-inflammatory drugs, corticosteroids, and antibiotics significantly reduces the failure in the treatment of severe disease of Community Acquired Pneumonia (CAP), infectious disease that carries a higher mortality in developed countries and that affects the lungs of those who have not recently been hospitalized. This is demonstrated by the results of a study published in the Journal of the American Medical Association (JAMA) and leading scientists of the Hospital Clinic of Barcelona, the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) and the Centre for Biomedical Research Network for Respiratory Diseases.
Associated with a mortality of between 10% and 31%, this condition is usually caused by bacteria, but may also have a viral origin. Pneumonia caused by bacteria should be treated with antibiotics and although treatment is performed properly mortality may be elevated in severe cases. Over time there has been speculation about whether reducing inflammation caused by pneumonia can also improve the outcome of these patients.
The study led by researchers from Barcelona is confirmed. During research, there has been administered antibiotics with placebo in a group of patients with corticosteroids and antibiotics to another group of patients. All of them suffer from severe, with more than eight years of evolution (2004-2012) pneumonia. The research results show that in patients who received antibiotics besides anti-inflammatory drugs had a significant reduction in treatment failure.
This study opens a new perspective in the treatment of severe pneumonia and a significant change in clinical practice to reduce mortality caused by this respiratory infection so common and potentially fatal. CAP affects about three people per 100,000 inhabitants per year, which can increase to 60 cases per year in people over 65 and in patients with respiratory, cardiac or hepatic chronic diseases.